We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Humoral and cellular responses after a third dose of SARS-CoV-2 mRNA vaccine in patients with glomerular disease.
- Authors
Teisseyre, Maxime; Graça, Daisy; Re, Daniel; Cremoni, Marion; Benzaken, Sylvia; Zorzi, Kévin; Fernandez, Céline; Esnault, Vincent L M; Barrière, Jérôme; Brglez, Vesna; Seitz-Polski, Barbara
- Abstract
To conclude, our data support the administration of a booster dose of SARS-CoV-2 mRNA vaccine in patients with glomerular disease to ensure an effective immune response against SARS-CoV-2. Third, our cohort was heterogeneous: (i) 25% of patients had received anti-CD20 treatment in the 12 months prior to dose 3; (ii) all but 2 patients had B-cell reconstitution; and (iii) 9 of 32 patients actually had nephrotic syndrome at the time of dose 3. Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly effective in the healthy population but is less effective in immunocompromised patients such as patients with organ transplant, solid cancer, lymphoid malignancies or recent treatments with an anti-CD20 monoclonal antibody [[1], [3], [5], [7]].
- Subjects
COVID-19 vaccines; HUMORAL immunity; KIDNEY glomerulus diseases; SARS-CoV-2; FOCAL segmental glomerulosclerosis
- Publication
Nephrology Dialysis Transplantation, 2023, Vol 38, Issue 1, p249
- ISSN
0931-0509
- Publication type
Article
- DOI
10.1093/ndt/gfac294